The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Nanotechnology-based strategies for treatment of ocular disease
Open accessAbstract
Ocular diseases include various anterior and posterior segment diseases. Due to the unique anatomy and physiology of the eye, efficient ocular drug delivery is a great challenge to researchers and pharmacologists. Although there are conventional noninvasive and invasive treatments, such as eye drops, injections and implants, the current treatments either suffer from low bioavailability or severe adverse ocular effects. Alternatively, the emerging nanoscience and nanotechnology are playing an important role in the development of novel strategies for ocular disease therapy. Various active molecules have been designed to associate with nanocarriers to overcome ocular barriers and intimately interact with specific ocular tissues. In this review, we highlight the recent attempts of nanotechnology-based systems for imaging and treating ocular diseases, such as corneal d iseases, glaucoma, retina diseases, and choroid diseases. Although additional work remains, the progress described herein may pave the way to new, highly effective and important ocular nanomedicines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global estimates of visual impairment: 2010
Pascolini, D., & Mariotti, S. P. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-300539 · Cited by 3,763
The Impact of Nanoscience on Heterogeneous Catalysis
Bell, A. T. (2003) · Science · doi:10.1126/science.1083671 · Cited by 2,510
Åkerman, M. E., Chan, W. C. W., Laakkonen, P., Bhatia, S. N., & Ruoslahti, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152463399 · Cited by 1,437
Preservatives in eyedrops: The good, the bad and the ugly
Baudouin, C., Labbé, A., Liang, H., Pauly, A., & Brignole-Baudouin, F. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.03.001 · Cited by 1,084
The physics, biophysics and technology of photodynamic therapy
Wilson, B. C., & Patterson, M. S. (2008) · Physics in Medicine and Biology · doi:10.1088/0031-9155/53/9/r01 · Cited by 1,006
Challenges and obstacles of ocular pharmacokinetics and drug delivery
Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.027 · Cited by 1,003
Nanoscience, Nanotechnology, and Chemistry
Whitesides, G. M. (2005) · Small · doi:10.1002/smll.200400130 · Cited by 719
Permeability of cornea, sclera, and conjunctiva: A literature analysis for drug delivery to the eye
Prausnitz, M. R., & Noonan, J. S. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js9802594 · Cited by 627
Recent Perspectives in Ocular Drug Delivery
Gaudana, R., Jwala, J., Boddu, S. H. S., & Mitra, A. K. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9694-0 · Cited by 605
Cunha-Vaz, J. (1979) · Survey of Ophthalmology · doi:10.1016/0039-6257(79)90158-9 · Cited by 423
Cited by
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Xia, Q., Zhang, Y., Li, Z., Hou, X., & Feng, N. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.01.011 · Cited by 665
Ocular drug delivery: present innovations and future challenges
Gote, V., Sikder, S., Sicotte, J., & Pal, D. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.256933 · Cited by 441
Han, H., Li, S., Xu, M., Zhong, Y., Fan, W., Xu, J., Zhou, T., Ji, J., Ye, J., & Yao, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114770 · Cited by 322
Niosomal drug delivery systems for ocular disease-recent advances and future prospects
Durak, S., Esmaeili Rad, M., Alp Yetisgin, A., Eda Sutova, H., Kutlu, O., Cetinel, S., & Zarrabi, A. (2020) · Nanomaterials · doi:10.3390/nano10061191 · Cited by 196
Metadata
- Authors
- Weng, Y., Liu, J., Jin, S., Guo, W., Liang, X., & Hu, Z.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 7
- Issue
- 3
- Pages
- 281-291
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W2550936658
- Cited by
- 375
- References
- 77
- FWCI
- 12.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanotechnology-based strategies for treatment of ocular disease. https://app.cochat.ai/papers/10.1016/j.apsb.2016.09.001
- The paper
- Weng, Y., Liu, J., Jin, S., Guo, W., Liang, X., & Hu, Z. (2017). Nanotechnology-based strategies for treatment of ocular disease. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2016.09.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
